What is the optimal management of pruritus in patients with primary biliary cholangitis?

Management of Pruritus in Primary Biliary Cholangitis

For moderate to severe pruritus in PBC, cholestyramine remains first-line therapy (4-16 g/day), followed by rifampicin (150-600 mg/day) as second-line, with naltrexone (starting at 12.5-25 mg/day) as third-line and sertraline as fourth-line treatment. 1

However, there is an important evolution in the evidence: The 2022 EASL guidelines on sclerosing cholangitis, which included PBC patients in the FITCH trial, now propose bezafibrate as first-line pharmacological treatment for moderate to severe pruritus, showing clear-cut benefit over placebo. 2

Stepwise Treatment Algorithm

Initial Assessment

• Rule out bile duct obstruction with imaging (ultrasound, MRCP, or ERCP) before initiating medical therapy 1
• Assess severity using visual analogue scale to track response 1

Non-Pharmacological Measures (All Patients)

• Use emollients to prevent skin dryness
• Avoid hot baths or showers
• Apply cooling gels (menthol-based) to affected areas
• Keep nails shortened 2

Pharmacological Treatment Ladder

First-Line: Cholestyramine

• Dose: 4 g up to four times daily (4-16 g/day total)
• Critical timing: Must be spaced at least 4 hours away from UDCA and other medications to avoid binding interactions 1
• Monitor fat-soluble vitamins (A, D, E, K) during long-term use 1
• Side effects: Constipation, bloating, poor palatability
• Palatability tip: Mix with orange squash and refrigerate overnight 3

Important caveat: The 2022 EASL sclerosing cholangitis guidelines note that evidence for cholestyramine effectiveness in cholestatic pruritus is limited compared to other agents, and it can impair UDCA absorption 2. The 2018 British dermatology guidelines actually recommend rifampicin as first-line based on meta-analyses showing superior efficacy 4.

Emerging First-Line Alternative: Bezafibrate

• The FITCH trial (largest RCT in the field) demonstrated clear benefit of bezafibrate versus placebo for moderate to severe pruritus in both PSC and PBC patients 2
• Provides sustained antipruritic effect plus additive anticholestatic benefits when combined with UDCA
• Well-tolerated with minimal side effects in short-term (3 weeks) and long-term (2 years) studies
• Monitor: Serum creatinine (may mildly increase), myalgia, transaminases
• This represents a paradigm shift from traditional bile acid sequestrant-first approach

Second-Line: Rifampicin

• Starting dose: 150 mg once or twice daily
• Titrate upward based on symptoms and liver function tests
• Maximum dose: 600 mg daily 1
• Critical monitoring: Check liver function tests at 2-4 weeks, then regularly
• Major risk: Drug-induced hepatitis occurs in up to 12% of cholestatic patients after 4-12 weeks (first 2 weeks considered safe) 2
• Warn patients about discoloration of urine, tears, and body secretions 1, 3
• Consider vitamin K supplementation if patient is icteric 3
• Evidence level: Strong (Level I/A1) 1; meta-analyses support efficacy 4

Third-Line: Naltrexone (Opioid Antagonist)

• Starting dose: 12.5-25 mg daily (NOT 50 mg initially)
• Target dose: 50 mg daily
• Critical warning: Start at very low dose to avoid opioid withdrawal-like syndrome (anxiety, confusion, pain, reduced pain threshold) 1, 2, 1, 2, 3
• Some patients may require intravenous naloxone induction phase with rapid dose escalation before converting to oral form 1
• Long-term tolerability issues: Ongoing withdrawal-like reactions, reduced pain threshold 3
• Only use after proven failure or intolerance to cholestyramine/resins and rifampicin 1

Fourth-Line: Sertraline (SSRI)

• Dose: 25-100 mg daily, titrate to symptoms and tolerance 1, 2, 1, 2, 3
• Mechanism unclear; presumed central neurotransmitter modulation 3
• Side effect: Dry mouth (warn patients) 3
• Evidence level: Weaker (Level II-2/C2) 1
• Clinical reality: Many clinicians find both naltrexone and sertraline disappointing in practice; importance of fully exploring cholestyramine and rifampicin first cannot be overstated 1

Refractory Pruritus Options

Fifth-Line Considerations:

• Gabapentin: Dose titrate as tolerated, though one small trial failed to show benefit over placebo 3. Anecdotal support exists 1. The 2018 British guidelines recommend NOT using gabapentin for hepatic pruritus 4
• Cimetidine: Anecdotal support only 1

Avoid:

• Antihistamines: Lack of efficacy for cholestatic itch (may help as sedative adjunct only) 1, 3
• Long-term sedating antihistamines: May predispose to dementia 4
• Ondansetron: Limited efficacy 1
• Phenobarbital: Excessive side-effect profile 1

Invasive/Specialized Approaches (Tertiary Centers)

For patients resistant to all medical therapies:

• Extracorporeal albumin dialysis (MARS) 1
• Plasmapheresis 1
• Albumin exchange 3
• Bile duct drainage (if obstruction present) 1
• UV light therapy (relatively accessible) 3
• Nasobiliary drainage (transient relief, technically complicated, pancreatitis risk) 3

Liver Transplantation

• Highly effective: Rapid reduction in pruritus (often within 24 hours) 3
• Reserved for "persistent and intractable" pruritus after all therapeutic trials have failed 1, 3
• Raises ethical issues of organ allocation for patients who wouldn't otherwise require transplantation 1

Key Clinical Pitfalls

1. Drug interaction with cholestyramine: Failure to space cholestyramine 4 hours away from UDCA and other medications reduces efficacy of both agents 1

2. Rifampicin hepatotoxicity: The 4-12 week window is critical for monitoring; don't assume safety beyond 2 weeks 2

3. Naltrexone initiation: Starting at full dose (50 mg) causes severe withdrawal symptoms; always start at 12.5-25 mg 2

4. Premature escalation: Clinical experience suggests many patients don't receive adequate trials of cholestyramine and rifampicin before moving to less effective agents 1

5. Ignoring bile duct obstruction: Always exclude mechanical obstruction before attributing pruritus solely to PBC 1

Divergence in Guidelines

The most significant evolution is the 2022 EASL sclerosing cholangitis guidelines proposing bezafibrate as first-line based on the FITCH trial, while the 2009 EASL PBC guidelines maintain cholestyramine as first-line [2 vs 1]. The 2018 British dermatology guidelines recommend rifampicin as first-line based on meta-analyses 4. The 2026 AGA/AASLD guidelines mention linerixibat (an ASBT inhibitor) for moderate to severe pruritus, representing emerging novel therapies 5, 6.

Given the superior RCT evidence from the FITCH trial and the practical limitations of cholestyramine (drug interactions, poor tolerability), bezafibrate or rifampicin should be strongly considered as first-line therapy for moderate to severe pruritus in PBC, with cholestyramine reserved for mild cases or as adjunctive therapy.